Abstract:Background Few data exist regarding use of nucleos(t)ide analogs started in early pregnancy for mothers with active chronic hepatitis B (CHB). We assessed the safety and efficacy of lamivudine/telbivudine initiated in the first trimester versus no treatment in mothers with active CHB. Methods We retrospectively enrolled 94 mothers newly diagnosed with active CHB in the first trimester of pregnancy. Patients with or without antiviral therapy were followed until postpartum week 28. All newborns received immunoprophylaxis. The primary endpoint was the safety of mothers and infants. The secondary endpoints were hepatitis B virus (HBV) DNA suppression and mother-to-child transmission (MTCT) rate. Results Fifty-nine of the 94 mothers initiated lamivudine/telbivudine (27/32) in the first trimester of pregnancy; 35 received no treatment. At delivery, the viral load reduction was similar between lamivudine and telbivudine. Early initiation of lamivudine/telbivudine significantly increased the proportion of mothers achieving HBV DNA <10 6 copies/ml compared with those with no treatment (100 versus 42.42 %, p < 0.001). At postpartum week 28, the MTCT rate was significant lower in the treated group than in the control group (0/61 or 0 versus 4/34 or 11.76 %, p = 0.028). Lamivudine and telbivudine were well tolerated in the mothers except mild creatine kinase (CK) elevation. There existed no differences in gestational age, infant length and weight, Apgar score, adverse events, or birth defect rates between infants from treated and untreated mothers. Conclusions Treatment with lamivudine or telbivudine for active CHB in early pregnancy appears to be safe and effective for controlling maternal disease as well as interrupting MTCT.

Correction To: Safety and Efficacy of Lamivudine or Telbivudine Started in Early Pregnancy for Mothers with Active Chronic Hepatitis B

Corrigendum to “artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis”

Corrigendum: Investigating the relationship between hepatitis B virus infection and postpartum depression in Chinese women: a retrospective cohort study

Corrigendum to "Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients"

A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway: Erratum

Safety and Efficacy of Lamivudine or Telbivudine Started in Early Pregnancy for Mothers with Active Chronic Hepatitis B

Correction: Păcurar et al. Hepatitis B in Pediatric Population: Observational Retrospective Study in Romania. Life 2024, 14, 348

Author Correction: Prevalence and Characteristics of Hypoxic Hepatitis in the Largest Single-Centre Cohort of Avian Influenza A(H7N9) Virus-Infected Patients with Severe Liver Impairment in the Intensive Care Unit

Author Correction: BHMT Polymorphism and Susceptibility to PTE in Chinese Patients.

Correction To: Basiliximab Versus Rabbit Antithymocyte Globulin As Induction Therapy for Living-Related Renal Transplantation: a Single-Center Experience

Erratum: The role of the hepatitis B virus genome and its integration in the hepatocellular carcinoma

Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study

Erratum to: Irreversible phenotypic perturbation and functional impairment of B cells during HIV-1 infection

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Erratum: Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)

Safety and Efficacy of Telbivudine in Late Pregnancy to Prevent Mother‐to‐child Transmission of Hepatitis B Virus: A Multicenter Prospective Cohort Study

Correction: Corrigendum: Patient-specific Hepatocyte-Like Cells Derived from Induced Pluripotent Stem Cells Model Pazopanib-Mediated Hepatotoxicity

Erratum to: Transmission risk of patients with COVID-19 meeting discharge criteria should be interpreted with caution (Journal of Zhejiang University-SCIENCE B, (2020), 21, 5, (408-410), 10.1631/jzus.B2000117)

Efficacy and Safety of Lamivudine or Telbivudine in Preventing Mother-to-Child Transmission of Hepatitis B Virus: A Real-World Study

Prospective Cohort Study on the Efficacy and Safety of Telbivudine Used Throughout Pregnancy in Blocking Mother-to-child Transmission of Hepatitis B Virus.

Corrigendum to “sex Differences in HIV Treatment Outcomes and Adherence by Exposure Groups among Adults in Guangdong, China: A Retrospective Observational Cohort Study” [eclinicalmedicine 22 (2020) 100351]